Paclitaxel for Malignant Pleural Mesothelioma
Author Information
Author(s): J van Meerbeeck, C Debruyne, N van Zandwijk, PE Postmus, MC Pennucci, F van Breukelen, D Galdermans, H Groen, P Pinson, M van Glabbeke, E van Marck, G Giaccone
Primary Institution: University of Antwerp
Hypothesis
Does paclitaxel have any significant activity in treating chemotherapy-naive patients with malignant pleural mesothelioma?
Conclusion
Paclitaxel at the dose and schedule investigated in this trial had no major activity in the treatment of malignant pleural mesothelioma.
Supporting Evidence
- No major objective responses were observed in the study.
- Ten patients had stable disease, while the remaining showed disease progression.
- The median survival time was 39 weeks, with a 1-year survival rate of 30%.
Takeaway
Doctors tested a medicine called paclitaxel on patients with a serious lung disease, but it didn't help them get better.
Methodology
The study involved 25 chemotherapy-naive patients receiving paclitaxel intravenously every 3 weeks, with assessments of tumor response and toxicity.
Limitations
The study had a small sample size and no major objective responses were observed.
Participant Demographics
Patients were aged 18 to 75 years, with a performance status of 0 to 2.
Statistical Information
Confidence Interval
0% - 15%
Want to read the original?
Access the complete publication on the publisher's website